<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01400841</url>
  </required_header>
  <id_info>
    <org_study_id>BSE 300</org_study_id>
    <secondary_id>TP-01-013</secondary_id>
    <secondary_id>TP-01-023</secondary_id>
    <nct_id>NCT01400841</nct_id>
  </id_info>
  <brief_title>HAART Model 300 Annuloplasty Ring</brief_title>
  <official_title>A Prospective, Non-randomized, Multi-center Trial to Evaluate the Safety and Effectiveness of the HAART Model 300 Annuloplasty Ring When Used to Surgically Repair a Leaking Aortic Valve Using a 3-D Intra-annular Mounting Frame</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biostable Science &amp; Engineering</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biostable Science &amp; Engineering</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation is a prospective, non-randomized, multi-center trial to evaluate the
      safety and effectiveness of the HAART model 300 annuloplasty ring when used to surgically
      repair a leaking aortic valve using a 3-D intra-annular mounting frame
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortic Regurgitation, (also known as Aortic Insufficiency; AI), is the failure of the aortic
      valve to close completely during diastole which causes blood to flow from the aorta back into
      the left ventricle. Aortic Regurgitation (AR) is a frequent cause of both disability and
      death due to congestive heart failure, primarily in individuals forty or older, but can also
      occur in younger populations.

      Traditionally management of aortic regurgitation has been by aortic valve replacement,
      however, as has been observed in patients who have had mitral valve repair, the option of
      maintaining ones native aortic valve versus a replacement, either bioprosthetic or
      mechanical, can have added multiple benefits. The advantage of repair is the avoidance of
      prosthetic valve-related complications with bioprosthetic valves over 10-15 years or the need
      for anticoagulation with mechanical valves and the related problems of this therapy.
      Therefore, potentially aortic valve repair is a good option for patients with AR or AI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Outcome Measure: Event-free Survival</measure>
    <time_frame>1 month postprocedure</time_frame>
    <description>Event-free survival is defined as survival free from device-related death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Outcome Measure: Event-free Survival</measure>
    <time_frame>2 years postprocedure (extended follow-up)</time_frame>
    <description>Event-free survival is defined as survival free from device-related death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Outcome Measure: Aortic Valvular Regurgitation at 6 Months Postprocedure</measure>
    <time_frame>6 months postprocedure</time_frame>
    <description>Aortic valvular regurgitation assessed by transthoracic echocardiography and graded as None/Trace (0), Mild (1+), Moderate (2+), Moderate-to-Severe (3+), or Severe (4+)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Outcome Measure: Aortic Valvular Regurgitation at 2 Years Postprocedure</measure>
    <time_frame>2 years postprocedure (extended follow-up)</time_frame>
    <description>Aortic valvular regurgitation assessed by transthoracic echocardiography and graded as None/Trace (0), Mild (1+), Moderate (2+), Moderate-to-Severe (3+), or Severe (4+)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implant Procedure Success</measure>
    <time_frame>discharge or 14 days postprocedure, whichever comes first</time_frame>
    <description>Success is defined as the absence of specified adverse events evaluated through discharge or 14 days after the procedure:
Aortic annular dissection, rupture, or leaflet damage
Paravalvular leak &gt; +2 or requiring intervention
Mitral valve impingement due to implant
implant dehiscence/migration into aorta
implant dehiscence/migration into left ventricle
Hemodynamics requiring intervention
Other adverse event resulting in reoperation, explantation, or permanent disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant Procedure Success</measure>
    <time_frame>2 years postprocedure (extended follow-up)</time_frame>
    <description>Success is defined as the absence of specified adverse events evaluated through discharge or 14 days after the procedure:
Aortic annular dissection, rupture, or leaflet damage
Paravalvular leak &gt; +2 or requiring intervention
Mitral valve impingement due to implant
implant dehiscence/migration into aorta
implant dehiscence/migration into left ventricle
Hemodynamics requiring intervention
Other adverse event resulting in reoperation, explantation, or permanent disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actuarial Freedom From Clinical Cardiovascular Events</measure>
    <time_frame>1 month postprocedure</time_frame>
    <description>Freedom from specified clinical cardiovascular events 1 month postprocedure:
Device-related mortality
Complete heart block
Structural device failure
Endocarditis
Periprosthetic leak or dehiscence
Thromboembolism
Bleeding Event
Native Valve Deterioration
Valve Thrombosis
Hemolysis
Reoperation and explant at 1 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actuarial Freedom From Clinical Cardiovascular Events</measure>
    <time_frame>2 years postprocedure</time_frame>
    <description>Freedom from specified clinical cardiovascular events 2 years postprocedure:
Device-related mortality
Complete heart block
Structural device failure
Endocarditis
Periprosthetic leak or dehiscence
Thromboembolism
Bleeding Event
Native Valve Deterioration
Valve Thrombosis
Hemolysis
Reoperation and explant at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>6 months postprocedure</time_frame>
    <description>Event-free survival is defined as survival free from device-related death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Capacity Classification</measure>
    <time_frame>6 months postprocedure</time_frame>
    <description>Four classes describing the effect of cardiac disease on physical activity: Class I - disease does not limit activity; Class II - slight limitation; Class III - marked limitation; Class IV - inability to carry out any physical activity without discomfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Capacity Classification</measure>
    <time_frame>2 years postprocedure (extended follow-up)</time_frame>
    <description>Four classes describing the effect of cardiac disease on physical activity: Class I - disease does not limit activity; Class II - slight limitation; Class III - marked limitation; Class IV - inability to carry out any physical activity without discomfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Gradient - Change From Baseline</measure>
    <time_frame>Baseline, 6 months postprocedure</time_frame>
    <description>Transthoracic echocardiography parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Gradient - Change From Baseline</measure>
    <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
    <description>Transthoracic echocardiography parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Gradient - Change From Baseline</measure>
    <time_frame>Baseline, 6 months postprocedure</time_frame>
    <description>Transthoracic echocardiography parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Gradient - Change From Baseline</measure>
    <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
    <description>Transthoracic echocardiography parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Mass - Change From Baseline</measure>
    <time_frame>Baseline, 6 months postprocedure</time_frame>
    <description>Left ventricular mass. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Mass - Change From Baseline</measure>
    <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
    <description>Left ventricular mass. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVID Diastole - Change From Baseline</measure>
    <time_frame>Baseline, 6 months postprocedure</time_frame>
    <description>Left ventricular internal dimension. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVID Diastole - Change From Baseline</measure>
    <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
    <description>Left ventricular internal dimension. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVID Systole - Change From Baseline</measure>
    <time_frame>Baseline, 6 months postprocedure</time_frame>
    <description>Left ventricular internal dimension. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVID Systole - Change From Baseline</measure>
    <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
    <description>Left ventricular internal dimension. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Diastolic Volume - Change From Baseline</measure>
    <time_frame>Baseline, 6 months postprocedure</time_frame>
    <description>Left ventricular diastolic volume. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Diastolic Volume - Change From Baseline</measure>
    <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
    <description>Left ventricular diastolic volume. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Systolic Volume - Change From Baseline</measure>
    <time_frame>Baseline, 6 months postprocedure</time_frame>
    <description>Left ventricular systolic volume. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Systolic Volume - Change From Baseline</measure>
    <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
    <description>Left ventricular systolic volume. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF - Change From Baseline</measure>
    <time_frame>Baseline, 6 months postprocedure</time_frame>
    <description>Left ventricular ejection fraction. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF - Change From Baseline</measure>
    <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
    <description>Left ventricular ejection fraction. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Output - Change From Baseline</measure>
    <time_frame>Baseline, 6 months postprocedure</time_frame>
    <description>Stroke volume x heart rate. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Output - Change From Baseline</measure>
    <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
    <description>Stroke volume x heart rate. Transthoracic echocardiography parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Index - Change From Baseline</measure>
    <time_frame>Baseline, 6 months postprocedure</time_frame>
    <description>Hemodynamic parameter computed as cardiac output divided by body surface area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Index - Change From Baseline</measure>
    <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
    <description>Hemodynamic parameter computed as cardiac output divided by body surface area</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Aortic Regurgitation</condition>
  <arm_group>
    <arm_group_label>HAART 300 Annuloplasty Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HAART 300 Annuloplasty Device</intervention_name>
    <description>Implantation of device for aortic valve repair</description>
    <arm_group_label>HAART 300 Annuloplasty Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is 50 years old or older

          -  The subject has a tricuspid aortic valve morphology

          -  Patients with documented severe aortic insufficiency with aortic annular dilation
             without severe concomitant aortic stenosis

          -  Patients referred to center for documented moderate to severe Chronic aortic
             regurgitation (AR) associated with annular dilatation with or without cusp prolapse of
             one, two, or all three leaflets

          -  Patients with or without Sinotubular Junction (STJ) dilatation or aortic root
             aneurysms

          -  Patients who are free of coronary disease or those with evidence of minor stable (1-2
             vessel) coronary disease

          -  Subject is willing to comply with specified follow-up evaluations, including
             transesophageal echocardiography if there are inadequate images by transthoracic
             echocardiography (TTE) to assess the aortic valve

          -  The subject has signed the written informed consent

          -  The subject agrees to return for all follow-up evaluations for the duration of the
             study (i.e. geographically stable

          -  The subject is New York Hospital Association (NYHA) class II or III

        Exclusion Criteria:

          -  The subject has preexisting valve prosthesis in the atrial, the mitral, pulmonary,
             and/or tricuspid position

          -  The subject requires an additional valve replacement

          -  The subject's aortic valve morphology is not tricuspid

          -  The subject has active endocarditis

          -  Heavily calcified valves

          -  Valvular retraction with severely reduced mobility

          -  The subject has mixed stenosis and regurgitation of the aortic valve with predominant
             stenosis

          -  The subject requires a repair of the mitral or tricuspid valve with the use of an
             annuloplasty device

          -  Leukopenia

          -  Acute anemia (Hb &lt; 9mg%)

          -  Platelet count &lt;100,000 cell/mm3

          -  Need for emergency surgery for any reason

          -  History of bleeding diathesis or coagulopathy or the subject refuses blood
             transfusions

          -  Active infection requiring antibiotic therapy (if temporary illness, subjects may
             enroll 4 weeks after discontinuation of antibiotics)

          -  Subjects in whom transesophageal echocardiography (TEE) is contraindicated

          -  Non elective presentation

          -  Low Ejection Fraction (EF) EF &lt; 40%

          -  Life expectancy &lt; 1 year

          -  Rheumatic disease

          -  The subject has severe leaflet fenestration or leaflets damaged by endocarditis

          -  The subject is or will be participating in a concomitant research study of an
             investigational product or has participated in such a study within the 30 days prior
             to screening

          -  The subject is a minor, an illicit drug user, alcohol abuser, prisoner,
             institutionalized, or is unable to give informed consent

          -  The subject is pregnant or lactating

          -  This patient will not agree to return to the implant center for the required number of
             follow-up visits or is geographically unavailable for follow-up

          -  The subject has not signed and dated the study informed consent

          -  Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack
             (TIA)

          -  Myocardial infarction (MI) within one month of trial inclusion

          -  Have a known intolerance to titanium or polyester

          -  Sole therapy for correction for patients with aortic root aneurysm

          -  Subjects requiring simultaneous cardiac procedures

          -  The subject has asymptomatic AR and a left ventricular ejection fraction (LVEF) &gt; 50%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christof Stamm, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Heart Institute Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut klinicke a experimantalni mediciny</name>
      <address>
        <city>Prague</city>
        <zip>1958/9</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Heart Institute</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Heart Center Munich</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <results_first_submitted>September 30, 2016</results_first_submitted>
  <results_first_submitted_qc>September 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 22, 2016</results_first_posted>
  <last_update_submitted>November 27, 2016</last_update_submitted>
  <last_update_submitted_qc>November 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Insufficiency, Aortic Regurgitation, Aortic Valve Repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HAART 300 Annuloplasty Device</title>
          <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Study Phase (6 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16">2 of the 18 consented subjects did not receive the device</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extended Study Phase (2 Years)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13">1 subject refused further participation
1 subject death prior to agreeing to extended follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HAART 300 Annuloplasty Device</title>
          <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aortic Valvular Regurgitation</title>
          <description>Grade assigned to degree of aortic regurgitation determined by core laboratory analysis of echocardiogram: 0=None/trace, 1+=Mild, 2+=Moderate, 3+=Moderate-to-Severe, 4+=Severe</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Classification</title>
          <description>New York Heart Association Functional Capacity
Class I: no limitation of activity. Ordinary activity - no undue fatigue, palpitation, dyspnea, or anginal pain.
Class II: slight limitation of activity. Comfortable at rest. Ordinary activity - fatigue, palpitation, dyspnea, or anginal pain.
Class III: marked limitation of activity. Comfortable at rest. Less than ordinary activity - fatigue, palpitation, dyspnea, or anginal pain.
Class IV: no activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. Increased discomfort upon activity.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak gradient</title>
          <description>Echocardiographic parameter determined by core laboratory. n=14 (2 unavailable or not evaluable)</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean gradient</title>
          <description>Echocardiographic parameter determined by core laboratory. n=14 (2 unavailable or not evaluable)</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left ventricular (LV) mass</title>
          <description>Left ventricular mass. Echocardiographic parameter determined by core laboratory. n=11 (5 unavailable or not evaluable)</description>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="260.0" spread="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left ventricular internal dimension (LVID) diastole</title>
          <description>Left ventricular internal dimension. Echocardiographic parameter determined by core laboratory. n=11 (5 unavailable or not evaluable)</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.44" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LVID systole</title>
          <description>Left ventricular internal dimension. Echocardiographic parameter determined by core laboratory. n=7 (9 unavailable or not evaluable)</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.09" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LV diastolic volume</title>
          <description>Left ventricular diastolic volume. Echocardiographic parameter determined by core laboratory. n=10 (6 unavailable or not evaluable)</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180.7" spread="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LV systolic volume</title>
          <description>Left ventricular systolic volume. Echocardiographic parameter determined by core laboratory. n=10 (6 unavailable or not evaluable)</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.7" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left ventricular ejection fraction (LVEF)</title>
          <description>Left ventricular ejection fraction. Echocardiographic parameter determined by core laboratory. n=10 (6 unavailable or not evaluable)</description>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac output</title>
          <description>Echocardiographic parameter determined by core laboratory. n=9 (7 unavailable or not evaluable)</description>
          <units>l/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.77" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac index</title>
          <description>Cardiac index is the cardiac output divided by body surface area. n=9 (7 unavailable or not evaluable)</description>
          <units>l/min/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.41" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Outcome Measure: Event-free Survival</title>
        <description>Event-free survival is defined as survival free from device-related death</description>
        <time_frame>1 month postprocedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Outcome Measure: Event-free Survival</title>
          <description>Event-free survival is defined as survival free from device-related death</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="79.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Outcome Measure: Event-free Survival</title>
        <description>Event-free survival is defined as survival free from device-related death</description>
        <time_frame>2 years postprocedure (extended follow-up)</time_frame>
        <population>Extended follow-up participants</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Outcome Measure: Event-free Survival</title>
          <description>Event-free survival is defined as survival free from device-related death</description>
          <population>Extended follow-up participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75.3" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy Outcome Measure: Aortic Valvular Regurgitation at 6 Months Postprocedure</title>
        <description>Aortic valvular regurgitation assessed by transthoracic echocardiography and graded as None/Trace (0), Mild (1+), Moderate (2+), Moderate-to-Severe (3+), or Severe (4+)</description>
        <time_frame>6 months postprocedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy Outcome Measure: Aortic Valvular Regurgitation at 6 Months Postprocedure</title>
          <description>Aortic valvular regurgitation assessed by transthoracic echocardiography and graded as None/Trace (0), Mild (1+), Moderate (2+), Moderate-to-Severe (3+), or Severe (4+)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy Outcome Measure: Aortic Valvular Regurgitation at 2 Years Postprocedure</title>
        <description>Aortic valvular regurgitation assessed by transthoracic echocardiography and graded as None/Trace (0), Mild (1+), Moderate (2+), Moderate-to-Severe (3+), or Severe (4+)</description>
        <time_frame>2 years postprocedure (extended follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy Outcome Measure: Aortic Valvular Regurgitation at 2 Years Postprocedure</title>
          <description>Aortic valvular regurgitation assessed by transthoracic echocardiography and graded as None/Trace (0), Mild (1+), Moderate (2+), Moderate-to-Severe (3+), or Severe (4+)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Procedure Success</title>
        <description>Success is defined as the absence of specified adverse events evaluated through discharge or 14 days after the procedure:
Aortic annular dissection, rupture, or leaflet damage
Paravalvular leak &gt; +2 or requiring intervention
Mitral valve impingement due to implant
implant dehiscence/migration into aorta
implant dehiscence/migration into left ventricle
Hemodynamics requiring intervention
Other adverse event resulting in reoperation, explantation, or permanent disability.</description>
        <time_frame>discharge or 14 days postprocedure, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Procedure Success</title>
          <description>Success is defined as the absence of specified adverse events evaluated through discharge or 14 days after the procedure:
Aortic annular dissection, rupture, or leaflet damage
Paravalvular leak &gt; +2 or requiring intervention
Mitral valve impingement due to implant
implant dehiscence/migration into aorta
implant dehiscence/migration into left ventricle
Hemodynamics requiring intervention
Other adverse event resulting in reoperation, explantation, or permanent disability.</description>
          <units>percentage of implant procedures</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="79.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Procedure Success</title>
        <description>Success is defined as the absence of specified adverse events evaluated through discharge or 14 days after the procedure:
Aortic annular dissection, rupture, or leaflet damage
Paravalvular leak &gt; +2 or requiring intervention
Mitral valve impingement due to implant
implant dehiscence/migration into aorta
implant dehiscence/migration into left ventricle
Hemodynamics requiring intervention
Other adverse event resulting in reoperation, explantation, or permanent disability.</description>
        <time_frame>2 years postprocedure (extended follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Procedure Success</title>
          <description>Success is defined as the absence of specified adverse events evaluated through discharge or 14 days after the procedure:
Aortic annular dissection, rupture, or leaflet damage
Paravalvular leak &gt; +2 or requiring intervention
Mitral valve impingement due to implant
implant dehiscence/migration into aorta
implant dehiscence/migration into left ventricle
Hemodynamics requiring intervention
Other adverse event resulting in reoperation, explantation, or permanent disability.</description>
          <units>percentage of implant procedures</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="61.6" upper_limit="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actuarial Freedom From Clinical Cardiovascular Events</title>
        <description>Freedom from specified clinical cardiovascular events 1 month postprocedure:
Device-related mortality
Complete heart block
Structural device failure
Endocarditis
Periprosthetic leak or dehiscence
Thromboembolism
Bleeding Event
Native Valve Deterioration
Valve Thrombosis
Hemolysis
Reoperation and explant at 1 month</description>
        <time_frame>1 month postprocedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Actuarial Freedom From Clinical Cardiovascular Events</title>
          <description>Freedom from specified clinical cardiovascular events 1 month postprocedure:
Device-related mortality
Complete heart block
Structural device failure
Endocarditis
Periprosthetic leak or dehiscence
Thromboembolism
Bleeding Event
Native Valve Deterioration
Valve Thrombosis
Hemolysis
Reoperation and explant at 1 month</description>
          <units>percentage of implant procedures</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="79.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actuarial Freedom From Clinical Cardiovascular Events</title>
        <description>Freedom from specified clinical cardiovascular events 2 years postprocedure:
Device-related mortality
Complete heart block
Structural device failure
Endocarditis
Periprosthetic leak or dehiscence
Thromboembolism
Bleeding Event
Native Valve Deterioration
Valve Thrombosis
Hemolysis
Reoperation and explant at 2 years</description>
        <time_frame>2 years postprocedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Actuarial Freedom From Clinical Cardiovascular Events</title>
          <description>Freedom from specified clinical cardiovascular events 2 years postprocedure:
Device-related mortality
Complete heart block
Structural device failure
Endocarditis
Periprosthetic leak or dehiscence
Thromboembolism
Bleeding Event
Native Valve Deterioration
Valve Thrombosis
Hemolysis
Reoperation and explant at 2 years</description>
          <units>percentage of implant procedures</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" lower_limit="53.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival</title>
        <description>Event-free survival is defined as survival free from device-related death</description>
        <time_frame>6 months postprocedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival</title>
          <description>Event-free survival is defined as survival free from device-related death</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="79.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New York Heart Association (NYHA) Functional Capacity Classification</title>
        <description>Four classes describing the effect of cardiac disease on physical activity: Class I - disease does not limit activity; Class II - slight limitation; Class III - marked limitation; Class IV - inability to carry out any physical activity without discomfort</description>
        <time_frame>6 months postprocedure</time_frame>
        <population>NYHA evaluation not done on 1 of 15 participants</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>New York Heart Association (NYHA) Functional Capacity Classification</title>
          <description>Four classes describing the effect of cardiac disease on physical activity: Class I - disease does not limit activity; Class II - slight limitation; Class III - marked limitation; Class IV - inability to carry out any physical activity without discomfort</description>
          <population>NYHA evaluation not done on 1 of 15 participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New York Heart Association (NYHA) Functional Capacity Classification</title>
        <description>Four classes describing the effect of cardiac disease on physical activity: Class I - disease does not limit activity; Class II - slight limitation; Class III - marked limitation; Class IV - inability to carry out any physical activity without discomfort</description>
        <time_frame>2 years postprocedure (extended follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>New York Heart Association (NYHA) Functional Capacity Classification</title>
          <description>Four classes describing the effect of cardiac disease on physical activity: Class I - disease does not limit activity; Class II - slight limitation; Class III - marked limitation; Class IV - inability to carry out any physical activity without discomfort</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Gradient - Change From Baseline</title>
        <description>Transthoracic echocardiography parameter</description>
        <time_frame>Baseline, 6 months postprocedure</time_frame>
        <population>Baseline measure not available for 1 of 15 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Gradient - Change From Baseline</title>
          <description>Transthoracic echocardiography parameter</description>
          <population>Baseline measure not available for 1 of 15 participants.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Gradient - Change From Baseline</title>
        <description>Transthoracic echocardiography parameter</description>
        <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
        <population>Baseline measure not available for 1 of 11 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Gradient - Change From Baseline</title>
          <description>Transthoracic echocardiography parameter</description>
          <population>Baseline measure not available for 1 of 11 participants.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Gradient - Change From Baseline</title>
        <description>Transthoracic echocardiography parameter</description>
        <time_frame>Baseline, 6 months postprocedure</time_frame>
        <population>Baseline measure not available for 1 of 15 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Gradient - Change From Baseline</title>
          <description>Transthoracic echocardiography parameter</description>
          <population>Baseline measure not available for 1 of 15 participants.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Gradient - Change From Baseline</title>
        <description>Transthoracic echocardiography parameter</description>
        <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
        <population>Baseline measure not available for 1 of 11 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Gradient - Change From Baseline</title>
          <description>Transthoracic echocardiography parameter</description>
          <population>Baseline measure not available for 1 of 11 participants.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LV Mass - Change From Baseline</title>
        <description>Left ventricular mass. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 6 months postprocedure</time_frame>
        <population>Both baseline and 6-month measure available for 8 of 15 participants</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>LV Mass - Change From Baseline</title>
          <description>Left ventricular mass. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 6-month measure available for 8 of 15 participants</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.4" spread="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LV Mass - Change From Baseline</title>
        <description>Left ventricular mass. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
        <population>Both baseline and 2-year measure available for 6 of 11 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>LV Mass - Change From Baseline</title>
          <description>Left ventricular mass. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 2-year measure available for 6 of 11 participants.</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.3" spread="72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LVID Diastole - Change From Baseline</title>
        <description>Left ventricular internal dimension. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 6 months postprocedure</time_frame>
        <population>Both baseline and 6-month measure available for 8 of 15 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>LVID Diastole - Change From Baseline</title>
          <description>Left ventricular internal dimension. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 6-month measure available for 8 of 15 participants.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LVID Diastole - Change From Baseline</title>
        <description>Left ventricular internal dimension. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
        <population>Both baseline and 2-year measure available for 7 of 11 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>LVID Diastole - Change From Baseline</title>
          <description>Left ventricular internal dimension. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 2-year measure available for 7 of 11 participants.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LVID Systole - Change From Baseline</title>
        <description>Left ventricular internal dimension. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 6 months postprocedure</time_frame>
        <population>Both baseline and 6-month measure available for 5 of 15 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>LVID Systole - Change From Baseline</title>
          <description>Left ventricular internal dimension. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 6-month measure available for 5 of 15 participants.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LVID Systole - Change From Baseline</title>
        <description>Left ventricular internal dimension. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
        <population>Both baseline and 2-year measure available for 3 of 11 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>LVID Systole - Change From Baseline</title>
          <description>Left ventricular internal dimension. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 2-year measure available for 3 of 11 participants.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LV Diastolic Volume - Change From Baseline</title>
        <description>Left ventricular diastolic volume. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 6 months postprocedure</time_frame>
        <population>Both baseline and 6-month measure available for 7 of 15 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>LV Diastolic Volume - Change From Baseline</title>
          <description>Left ventricular diastolic volume. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 6-month measure available for 7 of 15 participants.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.9" spread="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LV Diastolic Volume - Change From Baseline</title>
        <description>Left ventricular diastolic volume. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
        <population>Both baseline and 2-year measure available for 5 of 11 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>LV Diastolic Volume - Change From Baseline</title>
          <description>Left ventricular diastolic volume. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 2-year measure available for 5 of 11 participants.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-75.4" spread="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LV Systolic Volume - Change From Baseline</title>
        <description>Left ventricular systolic volume. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 6 months postprocedure</time_frame>
        <population>Both baseline and 6-month measure available for 7 of 15 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>LV Systolic Volume - Change From Baseline</title>
          <description>Left ventricular systolic volume. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 6-month measure available for 7 of 15 participants.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.6" spread="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LV Systolic Volume - Change From Baseline</title>
        <description>Left ventricular systolic volume. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
        <population>Both baseline and 2-year measure available for 5 of 11 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>LV Systolic Volume - Change From Baseline</title>
          <description>Left ventricular systolic volume. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 2-year measure available for 5 of 11 participants.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.4" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LVEF - Change From Baseline</title>
        <description>Left ventricular ejection fraction. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 6 months postprocedure</time_frame>
        <population>Both baseline and 6-month measure available for 7 of 15 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>LVEF - Change From Baseline</title>
          <description>Left ventricular ejection fraction. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 6-month measure available for 7 of 15 participants.</population>
          <units>percentage of blood volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.13" spread="6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LVEF - Change From Baseline</title>
        <description>Left ventricular ejection fraction. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
        <population>Both baseline and 2-year measure available for 5 of 11 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>LVEF - Change From Baseline</title>
          <description>Left ventricular ejection fraction. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 2-year measure available for 5 of 11 participants.</population>
          <units>percentage of blood volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.20" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Output - Change From Baseline</title>
        <description>Stroke volume x heart rate. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 6 months postprocedure</time_frame>
        <population>Both baseline and 6-month measure available for 7 of 15 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Output - Change From Baseline</title>
          <description>Stroke volume x heart rate. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 6-month measure available for 7 of 15 participants.</population>
          <units>l/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Output - Change From Baseline</title>
        <description>Stroke volume x heart rate. Transthoracic echocardiography parameter.</description>
        <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
        <population>Both baseline and 2-year measure available for 5 of 11 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Output - Change From Baseline</title>
          <description>Stroke volume x heart rate. Transthoracic echocardiography parameter.</description>
          <population>Both baseline and 2-year measure available for 5 of 11 participants.</population>
          <units>l/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Index - Change From Baseline</title>
        <description>Hemodynamic parameter computed as cardiac output divided by body surface area</description>
        <time_frame>Baseline, 6 months postprocedure</time_frame>
        <population>Both baseline and 6-month measure available for 7 of 15 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Index - Change From Baseline</title>
          <description>Hemodynamic parameter computed as cardiac output divided by body surface area</description>
          <population>Both baseline and 6-month measure available for 7 of 15 participants.</population>
          <units>l/min/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Index - Change From Baseline</title>
        <description>Hemodynamic parameter computed as cardiac output divided by body surface area</description>
        <time_frame>Baseline, 2 years postprocedure (extended follow-up)</time_frame>
        <population>Both baseline and 2-year measure available for 5 of 11 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>HAART 300 Annuloplasty Device</title>
            <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Index - Change From Baseline</title>
          <description>Hemodynamic parameter computed as cardiac output divided by body surface area</description>
          <population>Both baseline and 2-year measure available for 5 of 11 participants.</population>
          <units>l/min/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 6 months for 16 participant receiving the implant and through 2 years for 13 of the 16 participants in extended follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HAART 300 Annuloplasty Device</title>
          <description>Implantation of HAART 300 Annuloplasty Device for aortic valve repair
HAART 300 Annuloplasty Device: Implantation of device for aortic valve repair</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>aortic insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>central venous catheter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>primary coxarthrosis left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>radial fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>choreiform movement disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>postop delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>subcutaneous emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>enhanced plasma free hemoglobin value</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>arrhythmia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>conduction defects</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>intramural aortic hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>pericardial effusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>cicatrical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>reddening of wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthrosis left knee</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hip pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>leg pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>thoracal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>pulmonary mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>flickering in the eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>numbness of left little finger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>postoperative delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>symptomatic transitory psychotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>flu with fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>mild cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>clavus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>thrombophlebitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication by the investigator was not allowed until completion of the trial. All proposed publications must be cleared by unanimous vote of a publication committee consisting of the sponsor and representatives of the study investigators. Publication materials must be submitted for review at least 60 day in advance of publication. The Sponsor may embargo publication for 60 additional days to allow for patent filing or may prevent publication if filling of such application would be premature.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Wheeler</name_or_title>
      <organization>Biostable Science and Engineering, Inc.</organization>
      <phone>512-386-1996</phone>
      <email>John.wheeler@biostable-s-e.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

